Washington, DC 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2018




(Exact name of registrant as specified in its charter)




Delaware   001-32587   20-2726770

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)

910 Clopper Road, Suite 201S

Gaithersburg, Maryland

(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number including area code: (240) 654-1450


(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 2.02

Results of Operations and Financial Condition

On November 13, 2018, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended September 30, 2018. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference into such filing.


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits


No.    Description
99.1    Press Release dated November 13, 2018


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



/s/ William Brown

  Name: William Brown
  Title: Acting Chief Financial Officer

Dated November 13, 2018


Exhibit 99.1



Altimmune Announces Third Quarter 2018

Financial Results and Provides Corporate Update

GAITHERSBURG, Maryland, November 13, 2018 — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the three and nine months ended September 30, 2018.

Recent Corporate Highlights



Raised gross proceeds of $41.9 million in equity funding through October 10, 2018. After deducting the underwriter discount, placement agent fees, and other offering expenses the Company received net proceeds of approximately $37 million.



Announced additional positive data from its Phase 2a clinical study of its NasoVAX intranasal influenza vaccine candidate. The new data showed that serum antibody levels for NasoVAX were stable over a six-month time period when compared to Fluzone’s antibody levels, which declined by over 50% during the same time period. Additionally, a significant mucosal immune response was observed one month after vaccination when compared to both placebo and Fluzone®. As in the prior clinical studies, NasoVAX again had a clean safety profile. The Company previously announced positive results from the study in 60 healthy individuals, which demonstrated NasoVAX to be well-tolerated at all doses and showed 100% seroprotection at the two highest dose levels. Additionally, NasoVAX demonstrated the ability to elicit a significant T cell immune response as compared to Fluzone. These new data identify another potentially important type of immunity induced by NasoVAX and indicate that NasoVAX may have a higher likelihood of protection throughout the entire flu season.



Received an award of $2.5 million in additional BARDA funding to support NasoShield development. The funding is intended to allow vaccine characterization including key formulation parameters and batch consistency. Additionally, Altimmune will assay clinical samples from its ongoing Phase 1 clinical trial for mucosal immune response and compare different methods of administration in preclinical models.



Announced initial single-dose data from its Phase 1 study of NasoShield, an anthrax vaccine candidate. This portion of the ongoing study assessed the safety and immunogenicity of a single intranasal dose of NasoShield in four dose cohort levels and showed NasoShield to be safe and well-tolerated with no serious adverse events. The immunogenicity data suggest that NasoShield may require more than one dose for a robust immune response. The program is funded through a contract with the Biomedical Advanced Research and Development Authority (“BARDA”) which runs through September 2021 and, if all options are exercised, is expected to provide funding through the end of Phase 2 development. Immunogenicity data for the two-dose cohort will be available in the fourth quarter of 2018.



“The proceeds provided by our recent financings will allow us to invest significantly in the development of NasoVAX and to support our Company going forward,” said William J. Enright, Chief Executive Officer of Altimmune. “Our developing pipeline and novel approaches to vaccines are quite differentiated from other approaches making these large markets attractive opportunities for Altimmune.”

Third Quarter 2018 Financial Highlights



During the quarter the Company received $4.3 million of net proceeds from a registered direct offering which brought September 30, 2018 cash on hand to approximately $8.0 million.



Subsequent to quarter end, the Company received additional net proceeds of approximately $32.7 million related to its October 2 Underwritten Public Offering and October 10 Registered Direct Offering.



Third quarter revenue was $2.6 million compared to $4.6 million in the prior year period. Revenue fluctuated in proportion to our research and development expenses for the NasoShield and SparVax-L programs.



Research and development expenses were $4.7 million compared to $5.9 million in the prior year period. The decrease is primarily attributable to lower spending on NasoShield manufacturing when compared to the same period in 2017.



General and administrative expenses were $2.0 million as compared with $3.0 million for the same period in 2017. The decrease is primarily attributable to 2017 professional services related to the integration of the newly merged entity that did not recur in 2018.



Other Income (expense) was $0.9 million compared to ($0.5) million for the same period in 2017. The change was primarily due to the release of warrant liability associated with warrant exchanges consummated during the quarter.



Net loss attributed to common stockholders was $2.3 million compared to $31.9 million for the same period in 2017. The increase was due primarily to $26.6 million goodwill impairment in 2017 in addition to the activity described above.



About Altimmune

Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.

Forward-Looking Statement

Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. (the “Company”) may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: the terms of the Company’s Series B preferred stock offering and related warrants; our lack of financial resources and access to capital; realizing the benefits of the merger between Altimmune, Inc. and PharmAthene, Inc.; our ability to utilize the benefits of our tax assets and the results of a tax examination initiated by the IRS; clinical trials and the commercialization of proposed product candidates (such as marketing, regulatory, product liability, supply, competition, dependence on third parties and other risks); the regulatory approval process; dependence on intellectual property; the Company’s BARDA contract and other government programs, reimbursement and regulation. Further information on the factors and risks that could affect the Company’s business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, which are available at www.sec.gov.


Bill Enright     Ashley R. Robinson
President and CEO     Managing Director LifeSci Advisors
Phone: 240-654-1450     Phone: 617-535-7742








Three Months Ended

September 30,


Nine Months Ended

September 30,

     2018     2017     2018     2017  



Research grants and contracts

   $ 2,629,446     $ 4,565,251     $ 7,727,681     $ 7,892,919  

License revenue

     4,947       26,689       14,833       36,565  













Total revenue

     2,634,393       4,591,940       7,742,514       7,929,484  













Operating expenses


Research and development

     4,728,726       5,905,552       15,394,616       13,946,403  

General and administrative

     1,963,733       3,038,756       7,345,651       6,863,782  

Goodwill impairment charges

     —          26,600,000       490,676       26,600,000  













Total operating expenses

     6,692,459       35,544,308       23,230,943       47,410,185  













Loss from operations

     (4,058,066     (30,952,368     (15,488,429     (39,480,701













Other income (expense):


Changes in fair value of warrant liability, including gain (loss) on exchange

     806,224       (508,316     (2,874,484     (508,316

Changes in fair value of embedded derivatives

     185,768       (1,157     183,638       (1,157

Interest expense

     (166,946     (2,344     (169,737     (160,103

Interest income

     21,100       15,372       78,306       19,538  

Other income (expense)

     31,378       10,786       289,053       9,839  













Total other income (expense)

     877,524       (485,659     (2,493,224     (640,199













Net loss before income tax benefit

     (3,180,542     (31,438,027     (17,981,653     (40,120,900

Income tax benefit

     829,393       1,532,790       3,318,124       2,526,499  













Net loss

     (2,351,149     (29,905,237     (14,663,529     (37,594,401

Other comprehensive income (loss) – foreign currency translation adjustments

     —         (1,028,033     (463,177     (2,864,839













Comprehensive loss

   $ (2,351,149   $ (30,933,270   $ (15,126,706   $ (40,459,240













Net loss

   $ (2,351,149   $ (29,905,237   $ (14,663,529   $ (37,594,401

Preferred stock accretion, contributions, and dividends

     64,139       (1,962,072     (2,527,275     (2,125,141













Net loss attributed to common stockholders

   $ (2,287,010   $ (31,867,309   $ (17,190,804   $ (39,719,542













Weighted-average common shares outstanding, basic and diluted

     1,321,289       517,596       983,651       386,524  













Net loss per share attributed to common stockholders, basic and diluted

   $ (1.73   $ (61.57   $ (17.48   $ (102.76




















September 30,


    December 31,


Current assets:


Cash and cash equivalents

   $ 7,964,002     $ 8,769,465  

Restricted cash

     34,174       3,534,174  







Total cash, cash equivalents and restricted cash

     7,998,176       12,303,639  

Accounts receivable

     2,547,402       3,806,239  

Tax refund receivable

     976,523       6,361,657  

Prepaid expenses and other current assets

     443,929       994,332  







Total current assets

     11,966,030       23,465,867  

Property and equipment, net

     1,407,080       603,146  

Intangible assets, net

     38,339,086       38,722,270  

Other assets

     1,149,185       238,917  







Total assets

   $ 52,861,381     $ 63,030,200  








Current liabilities:


Notes payable

   $ 1,467,260     $ 49,702  

Accounts payable

     150,738       129,075  

Accrued expenses and other current liabilities

     6,532,924       3,625,257  

Current portion of deferred revenue

     19,753       19,753  

Current portion of deferred rent

     173,952       15,914  







Total current liabilities

     8,344,627       3,839,701  

Deferred income taxes

     2,891,634       5,938,402  

Other long-term liabilities

     1,941,932       4,574,507  







Total liabilities

     13,178,193       14,352,610  







Contingencies (Note 16)


Series B redeemable convertible preferred stock; $0.0001 par value; 16,000 shares designated; 0 and 12,177 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively

     —         9,281,767  

Stockholders’ equity:


Common stock, $0.0001 par value; 200,000,000 and 100,000,000 shares authorized; 1,726,198 and 609,280 shares issued; 1,725,630 and 608,499 shares outstanding at September 30, 2018 and December 31, 2017, respectively

     173       61  

Additional paid-in capital

     137,071,546       121,657,587  

Accumulated deficit

     (92,348,368     (77,684,839

Accumulated other comprehensive loss – foreign currency translation adjustments

     (5,040,163     (4,576,986







Total stockholders’ equity

     39,683,188       39,395,823  







Total liabilities and stockholders’ equity

   $ 52,861,381     $ 63,030,200